Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.82
+0.77001.35%
Post-market: 57.820.00000.00%16:15 EDT
Volume:4K
Turnover:234.97K
Market Cap:93.67M
PE:- -
High:57.82
Open:56.69
Low:56.69
Close:57.05
52wk High:64.60
52wk Low:42.76
Shares:1.62M
Float Shares:1.62M
Volume Ratio:0.17
T/O Rate:0.25%
Dividend:0.63
Dividend Rate:1.10%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30

New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector

TIPRANKS
·
Sep 30

US Drug Lobby Group PhRMA Names Former House Leader Cantor as CEO

Reuters
·
Sep 30

Cboe data shows mixed options sentiment in UnitedHealth with shares down 1.58%

TIPRANKS
·
Sep 30

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live
·
Sep 29

Cigna: Announces Exclusive Agreement with UnitedHealth Global to Endorse Ghb as Preferred International Health Insurer - Website

THOMSON REUTERS
·
Sep 29

Cigna Global Health Benefits Signs Exclusive Endorsement Deal with UnitedHealthcare Global

Reuters
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29